Pre-order Enquiry
Request Free Sample
Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2022
SKU ID : QYR-21348629 | Publishing Date : 18-Jul-2022 | No. of pages : 92
Detailed TOC of Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2022
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Anti-Platelet Drugs
1.2.3 Dual Antiplatelet Therapy Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2017-2028)
2.2 Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Region
2.2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Peripheral Arterial Disease (PAD) Therapeutics Market Dynamics
2.3.1 Peripheral Arterial Disease (PAD) Therapeutics Industry Trends
2.3.2 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
2.3.3 Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
2.3.4 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue
3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
3.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
3.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2021
3.5 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
3.7 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Type
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Application
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2017-2028)
6.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022)
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2017-2028)
7.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022)
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2017-2028)
9.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca Plc. (UK)
11.1.1 AstraZeneca Plc. (UK) Company Detail
11.1.2 AstraZeneca Plc. (UK) Business Overview
11.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.1.5 AstraZeneca Plc. (UK) Recent Development
11.2 Bayer HealthCare Pharmaceuticals (Germany)
11.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Detail
11.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
11.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
11.3 Bristol-Myers Squibb Company (US)
11.3.1 Bristol-Myers Squibb Company (US) Company Detail
11.3.2 Bristol-Myers Squibb Company (US) Business Overview
11.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.3.5 Bristol-Myers Squibb Company (US) Recent Development
11.4 Merck & Co., Inc. (US)
11.4.1 Merck & Co., Inc. (US) Company Detail
11.4.2 Merck & Co., Inc. (US) Business Overview
11.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.4.5 Merck & Co., Inc. (US) Recent Development
11.5 Proteon Therapeutics, Inc. (US)
11.5.1 Proteon Therapeutics, Inc. (US) Company Detail
11.5.2 Proteon Therapeutics, Inc. (US) Business Overview
11.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.5.5 Proteon Therapeutics, Inc. (US) Recent Development
11.6 Sanofi S.A. (France)
11.6.1 Sanofi S.A. (France) Company Detail
11.6.2 Sanofi S.A. (France) Business Overview
11.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.6.5 Sanofi S.A. (France) Recent Development
11.7 Symic Bio, Inc. (US)
11.7.1 Symic Bio, Inc. (US) Company Detail
11.7.2 Symic Bio, Inc. (US) Business Overview
11.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.7.5 Symic Bio, Inc. (US) Recent Development
11.8 TheraVasc Inc. (US)
11.8.1 TheraVasc Inc. (US) Company Detail
11.8.2 TheraVasc Inc. (US) Business Overview
11.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.8.5 TheraVasc Inc. (US) Recent Development
11.9 AnGes MG, Inc. (Japan)
11.9.1 AnGes MG, Inc. (Japan) Company Detail
11.9.2 AnGes MG, Inc. (Japan) Business Overview
11.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.9.5 AnGes MG, Inc. (Japan) Recent Development
11.10 Athersys, Inc. (US)
11.10.1 Athersys, Inc. (US) Company Detail
11.10.2 Athersys, Inc. (US) Business Overview
11.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.10.5 Athersys, Inc. (US) Recent Development
11.11 Betagenon AB (Sweden)
11.11.1 Betagenon AB (Sweden) Company Detail
11.11.2 Betagenon AB (Sweden) Business Overview
11.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.11.5 Betagenon AB (Sweden) Recent Development
11.12 miRagen Therapeutics, Inc. (US)
11.12.1 miRagen Therapeutics, Inc. (US) Company Detail
11.12.2 miRagen Therapeutics, Inc. (US) Business Overview
11.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.12.5 miRagen Therapeutics, Inc. (US) Recent Development
11.13 Multi Gene Vascular Systems Ltd (Israel)
11.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Detail
11.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
11.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
11.14 ViroMed Co. Ltd. (Korea)
11.14.1 ViroMed Co. Ltd. (Korea) Company Detail
11.14.2 ViroMed Co. Ltd. (Korea) Business Overview
11.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
11.14.5 ViroMed Co. Ltd. (Korea) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2022
List of TablesTable 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Anti-Platelet Drugs
Table 3. Key Players of Dual Antiplatelet Therapy Drugs
Table 4. Key Players of Others
Table 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2017-2022)
Table 9. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2023-2028)
Table 11. Peripheral Arterial Disease (PAD) Therapeutics Market Trends
Table 12. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
Table 13. Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
Table 14. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
Table 15. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players (2017-2022)
Table 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2021)
Table 18. Ranking of Global Top Peripheral Arterial Disease (PAD) Therapeutics Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
Table 22. Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2017-2022)
Table 26. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2023-2028)
Table 28. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2017-2022)
Table 30. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2023-2028)
Table 32. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 42. AstraZeneca Plc. (UK) Company Detail
Table 43. AstraZeneca Plc. (UK) Business Overview
Table 44. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 45. AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 46. AstraZeneca Plc. (UK) Recent Development
Table 47. Bayer HealthCare Pharmaceuticals (Germany) Company Detail
Table 48. Bayer HealthCare Pharmaceuticals (Germany) Business Overview
Table 49. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 50. Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 51. Bayer HealthCare Pharmaceuticals (Germany) Recent Development
Table 52. Bristol-Myers Squibb Company (US) Company Detail
Table 53. Bristol-Myers Squibb Company (US) Business Overview
Table 54. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 55. Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 56. Bristol-Myers Squibb Company (US) Recent Development
Table 57. Merck & Co., Inc. (US) Company Detail
Table 58. Merck & Co., Inc. (US) Business Overview
Table 59. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 60. Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 61. Merck & Co., Inc. (US) Recent Development
Table 62. Proteon Therapeutics, Inc. (US) Company Detail
Table 63. Proteon Therapeutics, Inc. (US) Business Overview
Table 64. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 65. Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 66. Proteon Therapeutics, Inc. (US) Recent Development
Table 67. Sanofi S.A. (France) Company Detail
Table 68. Sanofi S.A. (France) Business Overview
Table 69. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 70. Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 71. Sanofi S.A. (France) Recent Development
Table 72. Symic Bio, Inc. (US) Company Detail
Table 73. Symic Bio, Inc. (US) Business Overview
Table 74. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 75. Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 76. Symic Bio, Inc. (US) Recent Development
Table 77. TheraVasc Inc. (US) Company Detail
Table 78. TheraVasc Inc. (US) Business Overview
Table 79. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 80. TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 81. TheraVasc Inc. (US) Recent Development
Table 82. AnGes MG, Inc. (Japan) Company Detail
Table 83. AnGes MG, Inc. (Japan) Business Overview
Table 84. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 85. AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 86. AnGes MG, Inc. (Japan) Recent Development
Table 87. Athersys, Inc. (US) Company Detail
Table 88. Athersys, Inc. (US) Business Overview
Table 89. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 90. Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 91. Athersys, Inc. (US) Recent Development
Table 92. Betagenon AB (Sweden) Company Detail
Table 93. Betagenon AB (Sweden) Business Overview
Table 94. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) TherapeuticsProduct
Table 95. Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 96. Betagenon AB (Sweden) Recent Development
Table 97. miRagen Therapeutics, Inc. (US) Company Detail
Table 98. miRagen Therapeutics, Inc. (US) Business Overview
Table 99. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) TherapeuticsProduct
Table 100. miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 101. miRagen Therapeutics, Inc. (US) Recent Development
Table 102. Multi Gene Vascular Systems Ltd (Israel) Company Detail
Table 103. Multi Gene Vascular Systems Ltd (Israel) Business Overview
Table 104. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) TherapeuticsProduct
Table 105. Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 106. Multi Gene Vascular Systems Ltd (Israel) Recent Development
Table 107. ViroMed Co. Ltd. (Korea) Company Detail
Table 108. ViroMed Co. Ltd. (Korea) Business Overview
Table 109. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) TherapeuticsProduct
Table 110. ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022) & (US$ Million)
Table 111. ViroMed Co. Ltd. (Korea) Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Anti-Platelet Drugs Features
Figure 3. Dual Antiplatelet Therapy Drugs Features
Figure 4. Others Features
Figure 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application in 2021 & 2028
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Peripheral Arterial Disease (PAD) Therapeutics Report Years Considered
Figure 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region: 2021 VS 2028
Figure 13. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players in 2021
Figure 14. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2021
Figure 16. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2017-2028)
Figure 18. United States Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2017-2028)
Figure 22. Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2017-2028)
Figure 30. China Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2017-2028)
Figure 38. Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2017-2028)
Figure 42. Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. AstraZeneca Plc. (UK) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 45. Bayer HealthCare Pharmaceuticals (Germany) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 46. Bristol-Myers Squibb Company (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 47. Merck & Co., Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 48. Proteon Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 49. Sanofi S.A. (France) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 50. Symic Bio, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 51. TheraVasc Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 52. AnGes MG, Inc. (Japan) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 53. Athersys, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 54. Betagenon AB (Sweden) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 55. miRagen Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 56. Multi Gene Vascular Systems Ltd (Israel) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 57. ViroMed Co. Ltd. (Korea) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2017-2022)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Keyplayers in Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2022
AstraZeneca Plc. (UK)Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Request Sample
Request Discount
